Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Cancer Metastatic × Irinotecan × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 25 Pancreatic Neoplasms 15 Neuroblastoma 9 Neoplasm Metastasis 9 Colonic Neoplasms 7 Stomach Neoplasms 6 Sarcoma, Ewing 6 Rhabdomyosarcoma 5 Rectal Neoplasms 5 Neoplasms 5 Medulloblastoma 4 Esophageal Squamous Cell Carcinoma 4 Sarcoma 3 Recurrence 3 Ovarian Neoplasms 3 Osteosarcoma 3 Esophageal Neoplasms 3 Ependymoma 3 Endometrial Neoplasms 3 Cholangiocarcinoma 3 Adenocarcinoma Of Esophagus 3 Wilms Tumor 2 Uterine Cervical Neoplasms 2 Small Cell Lung Carcinoma 2 Pathologic Complete Response 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Fibrolamellar hepatocellular carcinoma 2 Colorectal Adenocarcinoma 2 Breast Neoplasms 2 Biliary Tract Neoplasms 2

Interventions

Gemcitabine 2 folfirinox 1 chloroquine diphosphate 1 balstilimab 1 Taxes 1 Paclitaxel 1 Oxaliplatin 1 Irinotecan 1 Injections 1 Drug Therapy 1 Cisplatin 1 Chloroquine 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04469556 2026-02-20

PASS-01

University Health Network, Toronto

Phase 2 Completed

Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡